The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants.Infectious Disease Modelling · 2026
   Article
2. SARS-CoV-2 vaccines elicit differential Fc effector functions.iScience · 2025
   Article
3. Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment.Applied mathematical modelling · 2023
   Article
4. Novel coronavirus mutations: Vaccine development and challenges.Microbial pathogenesis · 2022
   Review
5. COVID-19 vaccination challenges: A mini-review.Human vaccines & immunotherapeutics · 2022
   Review
6. Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2022
   Review

Corrections and comments

• Comment on
  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.2021

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as